37 citations
,
May 2004 in “Multiple Sclerosis Journal” This article highlights adverse skin reactions due to injectable therapies for MS, noting that while generally mild, some cases can progress to serious lesions requiring medical intervention.
18 citations
,
March 2006 in “Expert Review of Neurotherapeutics” This review outlines strategies for preventing, identifying, and managing complications related to current MS therapies and reports no new clinical results, emphasizing the growing complexity in MS treatment regimens.
January 2026 in “Open Science Framework” This scoping review aims to map existing literature on alopecia associated with multiple sclerosis disease-modifying therapies, exploring types, incidence, and potential mechanisms, while noting that observed cases may be related more to treatment-induced immune changes than the disease itself.
4 citations
,
May 2018 in “Journal of Neuro-Ophthalmology” This review describes the evolution of treatments for relapsing multiple sclerosis, highlighting that while newer potent monoclonal agents can potentially achieve disease remission, they also pose moderate to severe adverse event risks that healthcare providers must understand.
45 citations
,
July 2002 in “The Neurologist” This article reviews the challenges of using disease-modifying therapy for multiple sclerosis and offers strategies to improve treatment adherence and manage adverse effects, but reports no new clinical findings.
